Open AccessRole of PET imaging for biochemical recurrence following primary treatment for prostate cancer
Author(s) -
Samuel J. Galgano,
Roberto Valentín,
Jonathan McConathy
Publication year - 2018
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2018.06.09
Subject(s) - prostate cancer , medicine , biochemical recurrence , positron emission tomography , androgen deprivation therapy , recurrent prostate cancer , prostate , cancer , stage (stratigraphy) , radiation therapy , modalities , prostate specific antigen , oncology , medical physics , radiology , prostatectomy , paleontology , social science , sociology , biology
Prostate cancer is one of the most common cancers in men worldwide, and primary prostate cancer is typically treated with surgery, radiation, androgen deprivation, or a combination of these therapeutic modalities. Despite technical advances, approximately 30% of men will experience biochemical recurrent within 10 years of definitive treatment. Upon detection of a rise in serum prostate specific antigen (PSA), there is great need to accurately stage these patients to help guide further therapy. As a result, there are considerable efforts underway to establish the role of positron emission tomography (PET) in the diagnostic algorithm of biochemically recurrent prostate cancer. This manuscript provides an overview of PET tracers used for the detection and localization of prostate cancer in the setting of biochemical recurrence with a focus on PET tracers that are currently being used in clinical practice in the United States.